(88 days)
Not Found
No
The summary describes a physical medical device (oxygenator, reservoir, filter) and its performance characteristics, with no mention of software, algorithms, or data processing that would suggest AI/ML.
Yes
The device is intended for use in cardiopulmonary bypass circuits as a substitute for the lungs, to control temperature, and to filter blood, all of which are direct physiological interventions aimed at treating a medical condition during a cardiovascular procedure.
No
This device is intended for use in cardiopulmonary bypass circuits to substitute for the lungs, control temperature, and filter blood, which are therapeutic and supportive functions, not diagnostic ones.
No
The device description clearly indicates it is a physical medical device (membrane oxygenator, heat exchanger, arterial filter, reservoir) with a coating, not a software-only product.
Based on the provided text, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use clearly describes the device's function within a cardiopulmonary bypass circuit, acting as a substitute for the lungs, controlling temperature, and filtering blood. These are all functions performed on the patient's blood within the body's circulatory system during surgery.
- Device Description: The description reinforces this by detailing the components and their roles in the extracorporeal circulation process.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (like blood, tissue, or urine) outside the body to provide information for diagnosis, monitoring, or screening.
IVDs are used to analyze samples in vitro (in glass or outside the living organism) to gain diagnostic or other clinical information. This device operates in vivo (within the living organism) or extracorporeally but directly connected to the patient's circulation.
N/A
Intended Use / Indications for Use
SYNTHESIS Ph.I.S.I.O. is a sterile, nonpyrogenic device intended for use in cardiopulmonary bypass circuits as substitute for the lungs (transfer of oxygen and removal of carbon dioxide), to control the arterial/venous temperature, and as venous blood reservoir and filter element to eliminate gas emboli and remove blood component aggregates larger than 40 m. SYNTHESIS Ph.I.S.I.O. is an adult oxygenator intended for use in operations on adult patients. SYNTHESIS Ph.I.S.I.O. must not be used for longer than 6 hours. Contact with blood for longer periods is inadvisable.
Synthesis M Ph.I.S.I.O. is intended for use in cardiopulmonary bypass circuits as substitute for the lungs (transfer of oxygen and removal of carbon dioxide), to control the arterial/venous temperature, and as filter element to eliminate gas emboli and remove blood component aggregates larger than 40 µm. Synthesis M Ph.I.S.I.O. is an adult oxygenator intended for use in operations on adult patients. Synthesis M Ph.I.S.I.O. must not be used for longer than 6 hours. Contact with blood for longer periods is inadvisable.
Synthesis R Ph.I.S.I.O. has been specifically designed for cardiovascular procedures requiring cardiopulmonary by-pass. It collects venous blood and it defoams, filters and stores the blood from the operating field through thoracic, intracardiac and general suction. Synthesis R Ph.I.S.I.O. can be used postoperatively for chest drainage. It is suggested not to use Synthesis R Ph.I.S.I.O. for more than 6 hours,
Synthesis C Ph.I.S.I.O. is intended for use in cardiopulmonary bypass circuits as substitute for the lungs (transfer of oxygen and removal of carbon dioxide), to control the arterial/venous temperature, and as venous blood reservoir and filter element to eliminate gas emboli and remove blood component aggregates larger than 40 µm. Synthesis C Ph.I.S.I.O. is an adult oxygenator intended for use in operations on adult patients. Synthesis C Ph.I.S.I.O. must not be used for longer than 6 hours. Contact with blood for longer periods is inadvisable,
Product codes (comma separated list FDA assigned to the subject device)
DTZ
Device Description
SYNTHESIS Ph.I.S.I.O. Adult Membrane Oxygenator With Integrated Arterial Filter and Hardshell Venous/Cardiotomy Reservoir with PhosphoryIcholine (Ph.I.S.I.O.) hereinafter called the SYNTHESIS Ph.I.S.I.O., is a high efficiency microporous hollow fiber membrane oxygenator integrated with a heat exchanger and an arterial filter and connected to a hardshell cardiotomy venous reservoir. The SYNTHESIS Ph.I.S.I.O. (and other modified versions) have been modified for the change in coating material applied to the arterial filter and for some ergonomic and cosmetic enhancements. The arterial filter of the device is now coated with a new coating containing the same phosphorylcholine monomer currently used for coating of the device. No modification to the intended use has been made as result of the modifications.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Adult
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Biocompatibility Testing:
A complete battery of tests were carried out in accordance with the requirements of ISO 10993-1:1995 and the FDA May 1, 1995 Memorandum on the use of the ISO 10993 standard for biocompatibility testing on the raw materials. Testing was performed on the SYNTHESIS Ph.I.S.I.O. (accelerated aging). The device was tested for Hemolysis, Hemocompatibility (including thrombosis and blood compatibility study with human blood), Cytotoxicity, Irritation, Acute Systemic Toxicity and Mutagenicity, Sterility, Pyrogenicity. ETO residuals and package integrity testing were also conducted. The resting met established specifications.
In Vitro Test Results:
In vitro testing were carried out in accordance with the requirements of "Guidance for Cardiopulmonary Bypass Arterial line Blood Fitter 510(k) Submission" Final Guidance for industry and FDA issued on November 29, 2000; "Guidance for Blood Extracorporeal Blood Circuit Defoamer 510(k) Submission" Final Guidance for Industry and FDA issued on November 29, 2000 - ISO 15675:2001 "Cardiovascular implants and artificial organs - Cardiopulmonary bypass systems - Arterial line blood filters" and ISO 15674:2001 - "Cardiovascular implants and artificial organs - Hardshell cardiotomy/venous reservoir systems (with/without filter) and soft venous reservoir bags", where applicable for providing the data necessary to demonstrate both the substantial equivalence with the predicate device and also compliant with safety and effectiveness requirements. The device was aged up to 3 (+1 year considered as a worst case) was tested for: Arter Characterization (including Priming Efficiency, Pressure Drop, Hemolysis/Cell Depletion & Visual Inspection. Filtration Efficiency, Air Handling, Structural Integrity, Pressure Integrity); Stability of Coating (including Leaching Flaking of Coating, Cracking of Coating); Hardshell Cardiotomy(Venous Reservoir Characterization (including: Breakthrough Time and Volume, Graduated Scale Accuracy, Hemolysis/Cell Depletion, Filtration Efficiency). The results of these tests met established specifications. For comparative purposes, the same testing, when applicable, has been conducted also on the SYNTHESIS MIMESYS predicate device. This 510(k) crosses reference performance data previously submitted in the SYNTHESIS MIMESYS 510k (K031233) for the gas transfer studies, operating blood volumes, heat exchanger performance evaluation, uniformity of PC coating on coated surfaces, softshell venous reservoir characterization (micorembolic activity and filtration efficiency), residual blood volume, defoaming capacity and breakthroughtime and volume of the cardiotomy section as the above mentioned aspects are not affected by the modification. The shipping carton passed the basic testing and was still capable of providing adequate protection for further handling.
Key Results: The results of in vitro studies demonstrate that the SYNTHESIS Ph.I.S.I.O. (and other modified versions) devices perform in a manner substantially equivalent to the predicate devices. Biocompatibility studies demonstrate that the new phosphorylcholine-based coating is biocompatible and functional tests demonstrate that its performance is equivalent to the SYNTHESIS MIMESYS predicate device, according to its intended use. Additional testing has demonstrated the effectiveness of production techniques to assure that the oxygenator is sterile and non-pyrogenic.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.4350 Cardiopulmonary bypass oxygenator.
(a)
Identification. A cardiopulmonary bypass oxygenator is a device used to exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during open-heart surgery.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions.”
0
Ko73380
Synthesis Ph.I.S.I.O. Adult Oxygenator Sorin Group Italia S.r.I.
| 510(k) SUMMARY | |
|---|---|
| ---------------- | -- |
| SUBMITTER: | Sorin Group Italia S.r.l.
86, Via Statale 12 Nord
41037 Mirandola (MO) Italy | FEB 29 2008 |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| CONTACT PERSON: | Luigi Vecchi
Phone: 011 39 0535 29811
Fax: 011 39 0535 25229 | |
| DATE PREPARED: | November 30, 2007 | |
| DEVICE TRADE NAME: | SYNTHESIS Ph.I.S.I.O.: Adult Membrane Oxygenator
With Integrated Arterial Filter and Hardshell
Venous/Cardiotomy Reservoir with Phosphorylcholine
(Ph.I.S.I.O.) coating
SYNTHESIS C Ph.I.S.I.O.: Adult Membrane Oxygenator
With Integrated Arterial Filter and Softshell Venous
Reservoir with Phosphorylcholine (Ph.I.S.I.O.) coating
SYNTHESIS M Ph.I.S.I.O.: Adult Membrane Oxygenator
With Integrated Arterial Filter with Phosphoryulcholine
(Ph.I.S.I.O.) Coating
SYNTHESIS R Ph.I.S.I.O: Hardshell Venous and
Cardiotomy Reservoir with Phosphorylcholine
(Ph:I.S.I.O.) Coating | |
| COMMON NAME: | Hollow Fiber Membrane Oxygenator/Integrated Arterial
Filter/Reservoir
Hollow Fiber Membrane Oxygenator/Softshell Venous
Reservoir/Integrated Arterial Filter
Hollow Fiber Membrane Oxygenator/Integrated Arterial
Filter
Hollow Fiber Membrane Oxygenator/Integrated Arterial
Filter
Softshell Venous Reservoir | |
| CLASSIFICATION NAME: | Cardiopulmonary Bypass Oxygenator/ Cardiopulmonary
Bypass Heat Exchanger/ Cardiopulmonary Bypass
Blood Reservoir/ Cardiopulmonary Bypass Defoamer/
Cardiopulmonary Bypass Arterial Line Blood Filter | |
| PREDICATE DEVICES: | SYNTHESIS MIMESYS Adult Membrane Oxygenator
with Integrated Arterial Filter and Hardshell
Venous/Cardiotomy Reservoir Mimesys treated
(Phosphorylcholine coating hereinafter called PC
coating) (K031233)
SYNTHESIS C MIMESYS: Adult Membrane Oxygenator
With Integrated Arterial Filter and Softshell Venous
Reservoir Mimesys Treated (Phosphorylcholine coating
hereinafter called PC coating) | |
1
SYNTHESIS M MIMESYS Adult Membrane Oxygenator Integrated with Arterial Filter Mimesys treated (PhosphoryIcholine coating hereinafter called PC coating) SYNTHESIS R MIMESYS: Hardshell Venous and Cardiotomy Reservoir Mimesys treated (PhosphoryIcholine coating hereinafter called PC coating)
DEVICE DESCRIPTION:
SYNTHESIS Ph.I.S.I.O. Adult Membrane Oxygenator With Integrated Arterial Filter and Hardshell Venous/Cardiotomy Reservoir with PhosphoryIcholine (Ph.I.S.I.O.) hereinafter called the SYNTHESIS Ph.I.S.I.O., is a high efficiency microporous hollow fiber membrane oxygenator integrated with a heat exchanger and an arterial filter and connected to a hardshell cardiotomy venous reservoir. The SYNTHESIS Ph.I.S.I.O. (and other modified versions) have been modified for the change in coating material applied to the arterial filter and for some ergonomic and cosmetic enhancements. The arterial filter of the device is now coated with a new coating containing the same phosphorylcholine monomer currently used for coating of the device. No modification to the intended use has been made as result of the modifications.
INDICATION FOR USE:
SYNTHESIS Ph.I.S.I.O. is a sterile, nonpyrogenic device intended for use in cardiopulmonary bypass circuits as substitute for the lungs (transfer of oxygen and removal of carbon dioxide), to control the arterial/venous temperature, and as venous blood reservoir and filter element to eliminate gas emboli and remove blood component aggregates larger than 40 m. SYNTHESIS Ph.I.S.I.O. is an adult oxygenator intended for use in operations on adult patients. SYNTHESIS Ph.I.S.I.O. must not be used for longer than 6 hours. Contact with blood for longer periods is inadvisable.
TECHNOLOGICAL CHARACTERISTICS:
The SYNTHESIS Ph.I.S.I.O. Adult Membrane Oxygenator with Integrated Arterial Filter and Hardshell Venous/Reservoir with Phopsporilcholine (Ph.l.S.I.O.) coating, is essentially identical to the SYNTHESIS MIMESYS predicate device with respect to operating principles, control mechanisms and biocompatibility of the new phosphorylcholine coating. The major modification made to the SYNTHESIS Ph.I.S.I.O. (and other modified versions) is the application of the new phoshorylcholine coating on the integrated arterial filter. No modification has been made to the current phosphorylcholine coating already present on the entire oxygenating module with heat exchanger and hardshell venous reservoir (except the fillering media of the reservoir) and softshell venous reservoir. The hardshell venous reservoir present in both SYNTHESIS Ph.I.S.I.O. and SYNTHESIS MIMESYS predicate device share the same technological characteristics, operating principles and materials except for some ergonomic modifications to ensure a more effective use.
The oxygenator is ethylene oxide sterilized and has a nonpyrogenic fluid path. It is for single use only.
BIOCOMPATIBILITY TEST RESULTS:
A complete battery of tests were carried out in accordance with the requirements of ISO 10993-1:1995 and the FDA May 1, 1995 Memorandum on the use of the ISO 10993 standard for biocompatibility
2
| Synthesis Ph.I.S.I.O. Adult Oxygenator | Traditional 510(k) |
|---|---|
| Sorin Group Italia S.r.I. | November 30, 2007 |
testing on the raw materials. Testing was performed on the SYNTHESIS Ph.I.S.I.O. (accelerated aging). The device was tested for Hemolysis, Hemocompatibility (including thrombosis and blood compatibility study with human blood), Cytotoxicity, Irritation, Acute Systemic Toxicity and Mutagenicity, Sterility, Pyrogenicity. ETO residuals and package integrity testing were also conducted. The resting met established specifications.
IN VITRO TEST RESULTS:
In vitro testing were carried out in accordance with the requirements of "Guidance for Cardiopulmonary Bypass Arterial line Blood Fitter 510(k) Submission" Final Guidance for industry and FDA issued on November 29, 2000; "Guidance for Blood Extracorporeal Blood Circuit Defoamer 510(k) Submission" Final Guidance for Industry and FDA issued on November 29, 2000 - ISO 15675:2001 "Cardiovascular implants and artificial organs - Cardiopulmonary bypass systems - Arterial line blood filters" and ISO 15674:2001 - "Cardiovascular implants and artificial organs - Hardshell cardiotomy/venous reservoir systems (with/without filter) and soft venous reservoir bags", where applicable for providing the data necessary to demonstrate both the substantial equivalence with the predicate device and also compliant with safety and effectiveness requirements. The device was aged up to 3 (+1 year considered as a worst case) was tested for: Arter Characterization (including Priming Efficiency, Pressure Drop, Hemolysis/Cell Depletion & Visual Inspection. Filtration Efficiency, Air Handling, Structural Integrity, Pressure Integrity); Stability of Coating (including Leaching Flaking of Coating, Cracking of Coating); Hardshell Cardiotomy(Venous Reservoir Characterization (including: Breakthrough Time and Volume, Graduated Scale Accuracy, Hemolysis/Cell Depletion, Filtration Efficiency). The results of these tests met established specifications. For comparative purposes, the same testing, when applicable, has been conducted also on the SYNTHESIS MIMESYS predicate device. This 510(k) crosses reference performance data previously submitted in the SYNTHESIS MIMESYS 510k (K031233) for the gas transfer studies, operating blood volumes, heat exchanger performance evaluation, uniformity of PC coating on coated surfaces, softshell venous reservoir characterization (micorembolic activity and filtration efficiency), residual blood volume, defoaming capacity and breakthroughtime and volume of the cardiotomy section as the above mentioned aspects are not affected by the modification. The shipping carton passed the basic testing and was still capable of providing adequate protection for further handling.
The results of the study showed the device characteristics between SYNTHESIS Ph.I.S.I.O. and SYNTHESIS MIMESYS were comparable.
CONCLUSIONS:
The results of in vitro studies demonstrate that the SYNTHESIS Ph.I.S.I.O. (and other modified versions) devices perform in a manner substantially equivalent to the predicate devices. Biocompatibility studies demonstrate that the new phosphorylcholine-based coating is biocompatible and functional tests demonstrate that its performance is equivalent to the SYNTHESIS MIMESYS predicate device, according to its intended use. Additional testing has demonstrated the effectiveness of production techniques to assure that the oxygenator is sterile and non-pyrogenic.
3
Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of a human figure, with three overlapping profiles suggesting a sense of community or interconnectedness. The profiles are rendered in black and are positioned to the right of the text. The text, "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA," is arranged in a circular fashion around the figure.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
FEB 2 9 2008
Sorin Group Italia, S.r.1. c/o Mr. Barry Sall Principal Consultant Parexel Consulting 200 West Street West Street, Waltham, MA 02451-1163
Re: K073380
Synthesis Ph.I.S.I.O. Adult Membrane Oxygenator with Integrated Arterial Filter and Hardshell Venous/Cardiotomy Reservoir with Phosphorylcholine (Ph.J.S.I.O.) Coating Regulation Number: 21 CFR 870.4350 Regulation Name: Cardiopulmonary bypass oxygenators Regulatory Class: Class II Product Code: DTZ Dated: November 30, 2007 Received: December 3, 2007
Dear Mr. Sall:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Mr. Barry Sall
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours.
suma R. Wchmer
· Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Image /page/5/Picture/0 description: The image shows the logo for Sorin Group. The logo consists of a stylized graphic to the left of the text "SORIN GROUP" in all caps. Below the company name, in smaller letters, is the text "AT THE HEART OF MEDICAL TECHNOLOGY."
510(k) Number (if known): _长�73380
Device Name: Synthesis Ph.I.S.I.O. Adult Membrane Oxygenator with Integrated Arterial Filter and Hardshell Venous/Cardiotomy Reservoir with PhosphoryIcholine (Ph.1.S.I.O.) Coating
Indications For Use:
Synthesis Ph.J.S.I.O. is intended for use in cardiopulmonary bypass circuits as substitute for the lungs (transfer of oxygen and removal of carbon dioxide), to control the arterial/venous temperature, and as venous blood reservoir and filter element to eliminate gas emboli and remove blood component aggregates larger than 40 um. Synthesis Ph.I.S.I.O. is an adult oxygenator intended for use in operations on adult patients. Synthesis Ph.I.S.I.O. must not be used for longer than 6 hours. Contact with blood for longer periods is inadvisable.
Synthesis M Ph.I.S.I.O. Adult Membrane Oxygenator with Integrated Arterial Filter with PhosphoryIcholine (Ph.I.S.I.O.) Coating
Indications For Use:
Synthesis M Ph.1.S.I.O. is intended for use in cardiopulmonary bypass circuits as substitute for the lungs (transfer of oxygen and removal of carbon dioxide), to control the arterial/venous temperature, and as filter element to eliminate gas emboli and remove blood component aggregates larger than 40 µm. Synthesis M Ph.I.S.I.O. is an adult oxygenator intended for use in operations on adult patients. Synthesis M Ph.I.S.I.O. must not be used for longer than 6 hours. Contact with blood for longer periods is inadvisable.
Synthesis R Ph.I.S.I.O. Hardshell Venous/Cardiotomy Reservoir with Phosphorycholine (Ph.J.S.I.O.) Coating
Indications For Use:
Synthesis R Ph.I.S.I.O. has been specifically designed for cardiovascular procedures requiring cardiopulmonary by-pass. It collects venous blood and it defoams, filters and stores the blood from the operating field through thoracic, intracardiac and general suction. Synthesis R Ph.I.S.I.O. can be used postoperatively for chest drainage. It is suggested not to use Synthesis R Ph.I.S.I.O. for more than 6 hours,
Synthesis C Ph.I.S.I.O. Adult Membrane Oxygenator with Integrated Arterial Filter and Softshell Venous Reservoir with PhosphoryIcholine (Ph.I.S.I.O.) Coating
Indications For Use:
Synthesis C Ph.I.S.I.O. is intended for use in cardiopulmonary bypass circuits as substitute for the lungs (transfer of oxygen and removal of carbon dioxide), to control the arterial/venous temperature, and as venous blood reservoir and filter element to eliminate gas emboli and remove blood component aggregates larger than 40 µm. Synthesis C Ph.I.S.I.O. is an adult oxygenator intended for use in operations on adult patients. Synthesis C Ph.I.S.I.O. must not be used for longer than 6 hours. Contact with blood for longer periods is inadvisable,
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-the-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) |
|---|
| (Division Sign-Off) |
Division of Cardiovascular Devices
5 (UIK) Number Ko + 55 80